Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025
The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.2% during the forecast period. Increase in number of initiatives and rising awareness about cholera are major factors contributing toward market growth.
Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.In February 2013, the Government of Haiti launched a 10-year National Cholera Elimination Plan.
The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.
Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.
The Cholera Platform is working with the Global Task Force for Cholera Control (GTFCC) WASH working group. This association aims to develop a method for conducting case studies to control and prevent the disease.
Further key findings from the report suggest: • The global market size was estimated at USD 63.1 million in 2017 and is expected to register a CAGR of 8.2% from 2017 to 2025 • By product, Dukoral vaccine dominated the market in 2017. The dominance can be attributed to the positive outcomes of this vaccine in preventing the disease since 2004. Dukoral is considered to be safe and stable • The Vaxchora segment is expected to exhibit a lucrative CAGR over the forecast period owing to benefits associated with the vaccine, such as single dose immunization and reduced adverse effects • Asia Pacific held the largest share in 2017 due to factors such as increasing incidence and growing initiatives for raising awareness about the disease and vaccination • North America is anticipated to witness lucrative growth over the next decade due to a recent product launch and increasing number of travelers • Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc.
Our reports have been used by over 10K customers, including:
Executive Summary The mRNA technology finds its applications in many diseases including the Covid-19 vaccine. The market for mRNA is mostly driven by the Covid-19 vaccine besides its major usage in cancer therapies. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are...
This study ’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants.
Community Acquired Pneumonia (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Drugs in Development, 2021, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline...
Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines and Non-COVID-19 Vaccines to Reach $28.92 Billion and $1.69 Billion by 2025 and 2031, Respectively; BIS Research Study Market Report Coverage - mRNA Vaccines and Therapeutics Market Segmentation • Application – COVID-19...
The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Additionally,...
175 pages •
By The Business Research Company
• Jul 2021
Major players in the gynecology drugs market are Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Ferring Holding SA, Johnson & Johnson, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., and Sanofi. The global gynecology drugs market...
125 pages •
By Global Industry Analysts
• Apr 2021
- Global Clostridium Difficile Treatment Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Clostridium Difficile Treatment estimated at US$878.9 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 5.1% over the...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Exportin 1 - Drugs In Development, 2021 Summary Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Exportin 1 - Drugs In Development, 2021, outlays...
Stem Cell Transplantation
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.